Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

pembrolizumab 245 Nivolumab 141 Cisplatin 135 Cyclophosphamide 134 Paclitaxel 113 Carboplatin 108 Gemcitabine 98 Radiotherapy 83 Dexamethasone 83 Docetaxel 78 atezolizumab 68 Ipilimumab 68 Doxorubicin 62 Fluorouracil 60 Blood Specimen Collection 58 Bevacizumab 58 fludarabine 54 Rituximab 54 Etoposide 53 Oxaliplatin 52 Surveys and Questionnaires 49 Lenalidomide 49 Prednisone 48 Standard of Care 45 Magnetic Resonance Spectroscopy 45 Capecitabine 45 Radiosurgery 44 Cetuximab 44 lenvatinib 43 durvalumab 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Clonal Evolution × 1 year × Clear all

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡